Psilocybin Whole Mushroom for the Treatment of... — Clinical Trial Details

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

This Phase I, randomised, quadruple-masked trial (n=30) will evaluate the tolerability, safety, subjective experience, and efficacy of repeated administration of three different doses of psilocybin whole mushroom for the treatment of obsessive-compulsive disorder (OCD). Participants aged 18 years and older with moderate to severe OCD will be assigned to receive low (10 mg), medium (20 mg), or high (30 mg) doses of psilocybin, delivered in a chocolate matrix, over a 12-week period. Participants will undergo a preparation session with a study therapist before receiving the psilocybin doses, which will be spaced approximately three weeks apart. They will be monitored for safety during dosing sessions, with vital signs checked hourly, and will complete assessments using the Yale-Brown Obsessive Compulsive Scale and Visual Analogue Scale throughout the treatment and follow-up phases. After the treatment phase, participants will be contacted monthly for ongoing efficacy and safety assessments for a total of 12 months.

Detailed Description

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Study Arms & Interventions

Low dose 10 mg

experimental

Whole dried psilocybin mushroom containing 10 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Interventions

Psilocybin10 mg
via Oral• single dose

Middle dose 20 mg

experimental

Whole dried psilocybin mushroom containing 20 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Interventions

Participants

Ages

18 – ?

Sexes

All

BMI

Psychosis History

Inclusion Criteria

Aged 18 years old, and older
Have OCD (DSM-5) based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).
At least moderate severity: Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥16.
Failed at least one adequate trial of guideline concordant treatment.
Considered safe for independent living
Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:
* Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors
* Other active OCD treatments (cognitive behavioral therapy \[CBT\] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)
\* Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.
* 5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin
* Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks

Exclusion Criteria

Concurrent active substance use disorder, or a personal history of psychosis.
History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS)32
Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion. Examples include: 1) Cardiovascular conditions: lifetime history of stroke, lifetime myocardial infarction, uncontrolled hypertension (resting blood pressure \>140/90 mmHg), tachycardia (resting heart rate \>100 beats per minute), elongated QT interval corrected by Fridericia's formula (QTcF; interval \>450 msec), participants with existing valvular heart disease, or clinically significant arrhythmia (\<1 year prior to signing the ICF); 2) Metabolic conditions: subjects with diabetes should have a stable diabetes treatment regimen and no history of diabetic ketoacidosis, hyperglycemic coma, or no hypoglycemic episodes with glucose below 54 mg/dL in the 3 months prior to baseline, and fasting glucose \>70 mg/dL at baseline; 3) Severe renal impairment: eGFR \<45 mL/min/1.73 m²); and Liver failure: Child-Pugh Classes B and C.
Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
Clinically significant renal or hepatic impairment, per clinical judgment of a study physician
EKG QTc ≥ 450 msec
Psychiatric comorbidity that may represent an acute risk to their own or other's safety, including history of bipolar disorder (I or II) in the participant or first degree relative, as well as any family history of psychosis.
Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
Participants who are pregnant, breastfeeding, planning a pregnancy, or planning to donate sperm within three months post-last study drug administration.
Participants of childbearing potential or participants with partners of childbearing potential who engage in intercourse which could result in pregnancy are unwilling/unable to practice medically acceptable highly effective birth control (double barrier, oral and injectable pharmacological contraceptives, or surgical such as vasectomy or bilateral tubal occlusion) during the study and up to three months after the last study drug administration.
Suicide attempt within the 12 months prior to enrollment
Any condition for which MRI is contraindicated, at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.

Company

Product

Legal

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Detailed Description

Study Arms & Interventions

Low dose 10 mg

Interventions

Middle dose 20 mg

Interventions

Locations

High dose 30 mg

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details